reports
Swire Pacific Ltd: 1 director
A director at Swire Pacific Ltd sold 527,500 shares at 10.747HKD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
GFL Environmental Inc: 1 director
A director at GFL Environmental Inc sold/sold after exercising options 86,820 shares at 44.920CAD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's direc...
Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Resu...
Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update Company to host a today at 8:30 a.m. Eastern Time NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsychiatric disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today reported financia...
Eos Energy Enterprises Announces Participation in Upcoming Investor Co...
Eos Energy Enterprises Announces Participation in Upcoming Investor Conferences EDISON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Eos Energy Enterprises, Inc. (NASDAQ: EOSE) ("Eos" or the “Company”), a leading provider of safe, scalable, efficient, and sustainable zinc-based long duration energy storage systems, today announced its participation at two upcoming investor conferences in June. Chief Executive Officer Joe Mastrangelo and Chief Financial Officer Nathan Kroeker will be attending and presenting at the Stifel Cross Sector Insight Conference in Boston on Wednesday, June 5, 2024. Mr...
Kelly Reports First-Quarter 2024 Earnings
Kelly Reports First-Quarter 2024 Earnings Q1 operating earnings of $26.8 million, or up 34% on an adjusted basis Q1 revenue down following sale of European staffing operations; down 2.6% on an organic basis Q1 adjusted EBITDA margin increased 110 basis points to 3.2% driven by meaningful reduction in operating expenses resulting from business transformation initiatives and sale of European staffing operations Company expects further expansion of EBITDA margin from the planned Q2 2024 acquisition of Motion Recruitment Partners, LLC ("MRP") and ongoing transformation actions TROY, Mich., M...
Black Diamond Therapeutics Reports First Quarter 2024 Financial Result...
Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update Initial Phase 2 data of BDTX-1535 in 2L/3L EGFRm NSCLC patients on track for Q3 2024Enrollment ongoing in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC; initial data expected Q1 2025Presented real world evidence on the evolving EGFR mutation landscape in NSCLC, and the potential of BDTX-1535 across multiple lines of therapy at the 2024 AACR annual meetingPoster presentations upcoming June 1st at 2024 ASCO Annual Meeting on BDTX-1535 in GBM patients: Phase 1 dose-e...
Knight Therapeutics Enters into Exclusive Supply and Distribution Agre...
Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM® for Canada and Latin America MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an exclusive supply and distribution agreement with Ironshore Pharmaceuticals & Development, Inc., a wholly owned subsidiary of Ironshore Therapeutics, Inc. (“Ironshore”), granting Knight the rights to seek regulatory approval and com...
Thérapeutique Knight conclut une entente exclusive d’approvisionnement...
Thérapeutique Knight conclut une entente exclusive d’approvisionnement et de distribution avec Ironshore Pharmaceuticals & Development, Inc. pour JORNAY PM® pour le Canada et l’Amérique latine MONTRÉAL, 09 mai 2024 (GLOBE NEWSWIRE) -- Thérapeutique Knight Inc. (TSX : GUD) (« Knight »), société pharmaceutique spécialisée panaméricaine (hors États-Unis), a annoncé aujourd’hui la conclusion d’une entente exclusive d’approvisionnement et de distribution avec Ironshore Pharmaceuticals & Development, Inc., une filiale en propriété exclusive d’Ironshore Therapeutics, Inc. (« Ironshore »), octroy...
Warner Music Group Corp. Reports Results for Fiscal Second Quarter End...
Warner Music Group Corp. Reports Results for Fiscal Second Quarter Ended March 31, 2024 Financial Highlights Solid Results Driven by Growth Across Recorded Music and Music Publishing Recorded Music Results Underpinned by an Acceleration in Subscription StreamingMusic Publishing Delivered Revenue Growth of 19%Reiterating Full-Year Operating Cash Flow Conversion Guidance of 50-60% For the three months ended March 31, 2024 Total revenue increased 7%, the same in constant currencyNet income was $96 million versus $37 million in the prior-year quarterOperating income decreased 4% to $119 mil...
Zevra Therapeutics to Participate at Upcoming Investor Events
Zevra Therapeutics to Participate at Upcoming Investor Events CELEBRATION, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane, President and Chief Executive Officer of Zevra, will present at several upcoming investor events in May 2024. Additionally, management will be available for one-on-one meetings with registered attendees. Mr. McFarlane will present at The Citizens JMP Life Sciences Conference in New York, NY, on Tuesday, May 14, at 1 p.m. ET. Mr. McFarl...
SPS Commerce Acquires Traverse Systems
SPS Commerce Acquires Traverse Systems Acquisition expands company’s product portfolio in supply chain performance and optimization Company to host conference call today at 8:30 a.m. ET MINNEAPOLIS, May 09, 2024 (GLOBE NEWSWIRE) -- SPS Commerce, Inc. (NASDAQ: SPSC), a leader in retail supply chain cloud services, today announced the acquisition of Traverse Systems, an industry leading SaaS platform that provides retailers and their merchandise suppliers a unified view of supply chain performance to improve collaboration and enhance the consumer experience. Traverse Systems provid...
Knight Therapeutics Reports First Quarter 2024 Results
Knight Therapeutics Reports First Quarter 2024 Results MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2024. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. 2024 Highlights Financial results Revenues were $86,604, an increase of $4,007 or 5% over the same period in prior year driven by the growth of our key p...
Thérapeutique Knight déclare ses résultats du premier trimestre de 202...
Thérapeutique Knight déclare ses résultats du premier trimestre de 2024 MONTRÉAL, 09 mai 2024 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight » ou la « Société »), une société pharmaceutique spécialisée panaméricaine (à l’exclusion des É.-U.) de premier plan, a annoncé aujourd’hui ses résultats financiers pour le premier trimestre clos le 31 mars 2024. Tous les montants sont exprimés en milliers de dollars canadiens (sauf indication contraire), à l’exception du nombre d’actions et des montants par action. Faits saillants de 2024 Résultats financiers Produits des act...
CorMedix Inc. Reports First Quarter 2024 Financial Results and Provide...
CorMedix Inc. Reports First Quarter 2024 Financial Results and Provides Business Update Conference Call Scheduled for Today at 8:30 a.m. Eastern Time BERKELEY HEIGHTS, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the first quarter ended March 31, 2024 and provided an update on its business. Recent Corporate Highlights: On April 2, 2024, CMS published its HCPCS coding decision for DefenCath...
Wave Life Sciences Reports First Quarter 2024 Financial Results and Pr...
Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update RestorAATion-2 clinical trial of WVE-006 in AATD patients underway; expected proof-of-mechanism data in patients with AATD remains on track for 2024 INHBE program for obesity expected clinical trial initiation in 1Q 2025; preclinical data demonstrate weight loss similar to semaglutide, fat loss with no loss of muscle mass, and curtailed rebound weight gain upon cessation of semaglutide, with potential for dosing 1 – 2 times per year Continued momentum in GSK collaboration; adva...
Destination XL Group, Inc. to Announce First Quarter 2024 Financial Re...
Destination XL Group, Inc. to Announce First Quarter 2024 Financial Results on May 30, 2024 Company to Webcast Conference Call Live at 9:00 a.m. ET CANTON, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Destination XL Group, Inc. (NASDAQ: DXLG), the leading integrated commerce retailer of Big + Tall men’s clothing and shoes, announced today it will release its first quarter of fiscal 2024 financial results before the market opens on Thursday, May 30, 2024. President and Chief Executive Officer Harvey Kanter and Executive Vice President, Chief Financial Officer, and Treasurer Peter Stratton wil...
Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare...
Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Tuesday, May 14, 2024 at 3:05 PM ET at the RBC Capital Markets Global Healthcare Conference, where members of management will also host investor one-on-one meetings. A live webcast and replay of th...
Century Therapeutics Reports First Quarter 2024 Financial Results and ...
Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates - Announced plans to pursue additional autoimmune disease regulatory filings for its iPSC derived NK cell therapy, CNTY-101, beyond systemic lupus erythematosus (SLE) - Closed $60 million private placement led by Bain Capital Life Sciences supporting accelerated expansion in autoimmune disease - Acquired Clade Therapeutics bringing enhancement of Allo-Evasion™ platform and three preclinical stage αβ iT programs spanning across cancer and autoimmune diseases - Additional clinical data from Pha...
Cosa Resources Announces Summer Exploration Plans for Athabasca Basin ...
Vancouver, British Columbia--(Newsfile Corp. - May 9, 2024) - Cosa Resources Corp. (TSXV: COSA) (OTCQB: COSAF) (FSE: SSKU) ("Cosa" or the "Company") is pleased to announce its summer exploration plans for its portfolio of Athabasca Basin uranium projects.HighlightsDiamond drilling at Ursa to follow up positive winter drilling results and test second high priority target areaAmbient Noise Tomography (ANT) surveys to prioritize strike at Ursa and follow-up airborne survey results at OrionAirborne Electromagnetic (EM) and Gravity surveying at Aurora and Orbit to advance these shallow, prospectiv...
Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Ter...
Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan – New $38.7 million term loan with a May 2029 maturity –– $37.5 million royalty monetization financing based on future sales of LOQTORZI® and UDENYCA® – REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced it entered into a combined term loan and product royalty financing agreement with Barings that has allowed Coherus to fully pay off the remaining $75 million of its Pharmakon Advisors term loan. This further reduces the Company’s term loan...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.